Bangladesh authorizes clinical trials through two coordinated but sequential reviews: an ethics review anchored by the Bangladesh Medical Research Council (BMRC) and its National Research Ethics Committee (NREC), and a regulatory review by the Directorate General of Drug Administration (DGDA), the drug regulatory authority under the Ministry of Health and Family Welfare (MOHFW). Neither review substitutes for the other, and unlike some jurisdictions that permit parallel submission, Bangladesh generally requires ethics clearance to be secured before the DGDA application proceeds. This guide walks through the legal basis, the two-track review structure, the documents each body expects, and the review timelines DGDA has published, so research administrators and sponsors can plan a realistic submission calendar.
The legal and regulatory framework
DGDA’s authority over drug regulation, including clinical trials, traces to the Drugs Act, 1940, Bangladesh’s foundational pharmaceutical legislation, as elaborated by subsequent drug policy (including the Drug Policy 2016) and DGDA’s own clinical trial guidance. DGDA has issued Good Clinical Practice guidelines for trials on human subjects, commonly referenced as BGD-GCP, which are derived from ICH E6(R2) Good Clinical Practice, aligning Bangladesh’s trial-conduct expectations with the same international standard referenced by regulators such as India’s CDSCO, Pakistan’s DRAP, and the ICH founding members. DGDA has also issued more specific procedural guidance covering the clinical trial protocol approval application format and stated timelines, and standard operating procedures governing ethical approval routed through the NREC.
Because DGDA periodically reissues and renumbers this guidance, sponsors should treat any specific document reference as a starting point for verification against DGDA’s currently published guidelines rather than a fixed citation.
Who approves a trial: DGDA’s role
DGDA reviews and approves the clinical trial protocol itself, including subsequent amendments, addenda, site changes, and time extensions, and is also the body that authorizes import of investigational products into Bangladesh, which requires an accompanying GMP certificate and Certificate of Analysis. DGDA additionally approves the Clinical Research Organizations (CROs), institutions, and trial facilities involved in a study, with that approval subject to renewal roughly every two years, and DGDA carries out compliance inspections of CROs and oversight of institutional ethics committee activity. Phase I through Phase III trials fall within DGDA’s clearance authority.
A DGDA submission is expected to include, among other items: a completed clinical research protocol checklist, the ethics approval letter (see below, this generally must already be in hand), the Investigator’s Brochure, the informed consent form, GMP certificate and Certificate of Analysis for the investigational product, investigator CVs, study agreements, GCP training certificates for study staff, the case record form, and relevant standard operating procedures. Sponsors should confirm the current document checklist directly with DGDA, since procedural guidance in this area has been updated in recent cycles.
Ethics review: the BMRC / NREC and institutional committee requirement
Ethics oversight in Bangladesh runs through two possible layers. Individual institutions may maintain their own Institutional Review Board or ethics committee; DGDA guidance calls for a minimum of five members, including at least one non-scientist and one member external to the institution, and these institutional committees are themselves expected to be registered with DGDA and renewed on a roughly two-year cycle.
Separately, the Bangladesh Medical Research Council (BMRC) serves as secretariat for the National Research Ethics Committee (NREC), first established in 1979 and comprising nine to thirteen members, reported to include a lawyer, a female representative, a religious-affairs representative, and a biostatistician alongside scientific members. NREC review is generally required for trials involving new or unregistered drugs, new indications for existing drugs, and international collaborative research, and NREC is reported to meet roughly every two months. A BMRC/NREC submission typically requires the Ethical Clearance Application Form, a research proposal in BMRC’s required format, the informed consent form in both Bengali and English, a study budget, and evidence of prior scientific (institutional) review committee sign-off.
The practical sequencing point for sponsors: ethics clearance is treated as a prerequisite input to the DGDA application, not a parallel-track review; plan the ethics submission first, or early enough that its outcome is available before the DGDA protocol dossier is finalized.
Review timelines
DGDA has published stated processing targets for its own review, reportedly structured in stages: an initial screening step, a deficiency-notice step if the dossier is incomplete, and a final approval or disapproval decision once its review committee has met. Sponsors and administrators should verify current figures directly with DGDA before building a submission timeline around them, but as most recently reported: standard protocol review runs on the order of 60 working days where no deficiencies are raised, with an expedited or fast-track category reported at roughly 15 working days for eligible protocols, and amendments to an already-approved protocol reported at roughly 30 working days.
Institutional ethics committee review timelines are not uniformly fixed by regulation and are generally described only as occurring “within a reasonable time,” while NREC review is bounded by its periodic meeting cadence rather than a fixed calendar-day target. Because the ethics step is expected to complete before DGDA review begins, the NREC or institutional committee meeting schedule is often the practical pacing factor for an overall Bangladesh submission; sponsors should confirm current committee meeting dates rather than assuming a rolling review.
Trial registration
Bangladesh regulatory guidance calls for health research conducted in the country, including clinical trials, to be registered with BMRC. A dedicated BMRC clinical trial registry function has been described in DGDA/BMRC guidance, though the extent of a fully electronic public-facing registration system has varied over time; sponsors should confirm the current registration mechanism and any applicable requirement to additionally register on an ICMJE-acceptable primary registry (such as ClinicalTrials.gov) directly with BMRC, since many sponsoring institutions and journals require the latter regardless of local registration.
What sponsors and research administrators should plan for
- Two review tracks, one sequence. Build ethics review (institutional EC and/or BMRC/NREC) into the front of the timeline; DGDA review is not expected to begin in earnest without ethics clearance already secured.
- CRO and institutional approval status. Confirm that the CRO, institution, and trial site hold current DGDA approval and are not approaching their renewal window mid-study.
- Import authorization for investigational product. Budget lead time for DGDA’s import authorization of the investigational product, supported by GMP certification and Certificate of Analysis.
- Bilingual documentation. Informed consent materials are expected in both Bengali and English for BMRC submission; plan translation and back-translation quality control accordingly, consistent with the general practice covered in CASRAI’s guidance on the informed consent form (ICF).
- GCP training records. DGDA’s application checklist reportedly expects evidence of GCP training for study personnel; confirm current documentation requirements before dossier assembly.
How this differs from neighboring South and Southeast Asian pathways
Bangladesh’s two-body structure, a national ethics council (BMRC/NREC) operating ahead of and separately from the drug regulator (DGDA), is broadly similar in shape to India’s framework, where India’s Central Drugs Standard Control Organisation (CDSCO) likewise coordinates with institutional ethics committees, and to Pakistan’s, where Pakistan’s Drug Regulatory Authority (DRAP) requires its own separate ethics and regulatory sign-off. None of these systems are interchangeable: approval from one country’s regulator or ethics body does not carry over to another, and each requires an independent national submission, its own document set, and its own timeline. Sponsors running multi-country South Asian trials should treat Bangladesh, India, and Pakistan as three fully separate regulatory dossiers rather than a single regional filing.
Frequently asked questions
Which body approves clinical trials in Bangladesh?
The Directorate General of Drug Administration (DGDA), under the Ministry of Health and Family Welfare, approves the clinical trial protocol and authorizes import of investigational products. A separate ethics approval, from an institutional ethics committee and/or the BMRC’s National Research Ethics Committee, is required in addition to, and generally ahead of, DGDA’s review.
Is BMRC ethics approval the same as DGDA approval?
No. BMRC, through the NREC, reviews the ethical acceptability of the research; DGDA reviews and authorizes the regulatory/protocol and product-import elements of the trial. Both are required, and ethics clearance is generally expected to be in place before the DGDA application is finalized.
How long does DGDA clinical trial approval take?
DGDA has reported a standard protocol review target on the order of 60 working days where no deficiencies are found, a fast-track category of roughly 15 working days for eligible protocols, and roughly 30 working days for amendments to an already-approved protocol. These figures should be confirmed against DGDA’s current published guidance, since procedural timelines are periodically revised.
Do clinical trials in Bangladesh need to be registered?
Bangladesh guidance calls for health research, including clinical trials, to be registered with BMRC. Sponsors should also confirm whether registration on an internationally recognized primary registry is separately required or expected by their funder, institution, or target journal.
Does DGDA approve Clinical Research Organizations (CROs) as well as trials?
Yes. DGDA approves the CROs, institutions, and trial facilities involved in a study, with that approval subject to periodic renewal, and DGDA conducts compliance inspections of CRO activity.
This guide summarizes publicly available regulatory guidance current as of this writing. DGDA and BMRC periodically revise application checklists, fees, and stated timelines; sponsors and research administrators should confirm current requirements directly against DGDA’s and BMRC’s published guidance before building a submission plan.
